Show simple item record

dc.contributor.authorBrozovich, F. V.en_US
dc.contributor.authorNicholson, C. J.en_US
dc.contributor.authorDegen, C. V.en_US
dc.contributor.authorGao, Yuan Z.en_US
dc.contributor.authorAggarwal, M.en_US
dc.contributor.authorMorgan, K. G.en_US
dc.date.accessioned2018-10-04T14:57:51Z
dc.date.available2018-10-04T14:57:51Z
dc.date.issued2016-04-01
dc.identifierhttp://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000373783300007&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=6e74115fe3da270499c3d65c9b17d654
dc.identifier.citationFV Brozovich, CJ Nicholson, CV Degen, Yuan Z Gao, M Aggarwal, KG Morgan. 2016. "Mechanisms of Vascular Smooth Muscle Contraction and the Basis for Pharmacologic Treatment of Smooth Muscle Disorders." PHARMACOLOGICAL REVIEWS, Volume 68, Issue 2, pp. 476 - 532 (57). https://doi.org/10.1124/pr.115.010652
dc.identifier.issn0031-6997
dc.identifier.issn1521-0081
dc.identifier.urihttps://hdl.handle.net/2144/31453
dc.description.abstractThe smooth muscle cell directly drives the contraction of the vascular wall and hence regulates the size of the blood vessel lumen. We review here the current understanding of the molecular mechanisms by which agonists, therapeutics, and diseases regulate contractility of the vascular smooth muscle cell and we place this within the context of whole body function. We also discuss the implications for personalized medicine and highlight specific potential target molecules that may provide opportunities for the future development of new therapeutics to regulate vascular function.en_US
dc.format.extentp. 476 - 532en_US
dc.languageEnglish
dc.publisherAMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICSen_US
dc.relation.ispartofPHARMACOLOGICAL REVIEWS
dc.relation.isversionofhttps://doi.org/10.1124/pr.115.010652
dc.rightsAttribution 4.0 Internationalen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectAnimalsen_US
dc.subjectCalciumen_US
dc.subjectCytoskeletonen_US
dc.subjectEpigenomicsen_US
dc.subjectHumansen_US
dc.subjectMyosinsen_US
dc.subjectScience & technologyen_US
dc.subjectPharmacology & pharmacyen_US
dc.subjectMyosin light-chainen_US
dc.subjectDependent protein-kinaseen_US
dc.subjectPulmonary arterial hypertensionen_US
dc.subjectAngiotensin converting enzymeen_US
dc.subjectGenome-wide associationen_US
dc.subjectHigh blood pressureen_US
dc.subjectPhosphatase target subuniten_US
dc.subjectMesenteric small arteriesen_US
dc.subjectIntegrin-linked kinaseen_US
dc.subjectBlood pressureen_US
dc.subjectMuscle contractionen_US
dc.subjectLife sciences & biomedicineen_US
dc.subjectMuscle, smooth, vascularen_US
dc.subjectVascular diseasesen_US
dc.subjectPharmacology and pharmaceutical sciencesen_US
dc.subjectLong noncoding RNAsen_US
dc.titleMechanisms of vascular smooth muscle contraction and the basis for pharmacologic treatment of smooth muscle disordersen_US
dc.typeArticleen_US
dc.description.versionAccepted manuscripten_US
dc.identifier.doihttps://doi.org/10.1124/pr.115.010652
pubs.elements-sourceweb-of-scienceen_US
pubs.notesEmbargo: Not knownen_US
pubs.organisational-groupBoston Universityen_US
pubs.organisational-groupBoston University, College of Health & Rehabilitation Sciences: Sargent Collegeen_US
pubs.organisational-groupBoston University, College of Health & Rehabilitation Sciences: Sargent College, Health Sciencesen_US
pubs.publication-statusPublisheden_US


This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's license is described as Attribution 4.0 International